MyFinsight
Home
Blog
About
Proceeds received from
offering, net of issuance...
$3,990,814
Proceeds received from
stock option exercise
$887
Redemptions of marketable
securities
$692,250
(-95.47%↓ Y/Y)
Net cash flows
provided by financing...
$3,991,701
Net cash flows
provided by investing...
$692,250
(-89.87%↓ Y/Y)
Change in cash and cash
equivalents for the period
$1,742,374
(220.19%↑ Y/Y)
Canceled cashflow
$2,941,577
Change in fair value of
warrant liability
$2,127,379
Warrant issuance costs
$755,233
Loss on issuance of
warrants
$726,427
Accounts payable and
accrued expenses
$461,976
(-24.48%↓ Y/Y)
Stock-based compensation
$285,260
(-7.50%↓ Y/Y)
Vesting of restricted
common stock issued for...
$127,000
Realized loss on
redemption of equity...
$38,962
(-72.61%↓ Y/Y)
Non-cash lease
adjustments
$18,626
Depreciation and
amortization
$3,751
(-58.67%↓ Y/Y)
Net cash flows used
in operating...
-$2,940,913
(64.62%↑ Y/Y)
Effect of foreign
exchange rates on cash
-$664
(-102.16%↓ Y/Y)
Canceled cashflow
$4,544,614
Net loss
-$7,072,124
(20.25%↑ Y/Y)
Prepaid expenses and
other current assets
$363,207
(484.56%↑ Y/Y)
Unrealized loss (gain) on
equity securities
$27,238
(-83.73%↓ Y/Y)
Operating lease
liabilities
-$19,361
(80.37%↑ Y/Y)
Foreign currency
remeasurement gain
$3,550
(-97.26%↓ Y/Y)
Accretion of discounts on
available for sale debt...
$47
(-99.96%↓ Y/Y)
Back
Back
Cash Flow
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)
source: myfinsight.com